TCR2 Therapeutics announced promising Phase I data for gavo-cel in mesothelin-expression that points toward effects in multiple solid tumors, especially ovarian cancer.

Sam Ingram and Hui Tang reinforce the agency’s commitment to digital experience, and data and analytics.

Drug development can be done better, faster and less expensively. The industry is facing up to that reality, moving a variety of disruptive innovations forward with the blessing of regulators.

Technology has transformed the industry, significantly expanding pharma pipelines, facilitating more engagement, and empowering patients.

The greatest power of the new marketing technologies available to pharma brands may be their capacity to bring the beliefs and questions of real patients and HCPs into sharper view.

“We are disappointed with this outcome. The treatment of Alzheimer’s disease psychosis continues to be an area of high unmet need, for which there is no approved therapy,” said company CEO Steve Davis.

A Q&A with Wendy Carhart of Real Chemistry

Intercept Pharmaceuticals said it would resubmit its application for nonalcoholic steatohepatitis (NASH) treatment to the U.S. Food and Drug Administration based on new interim analysis of data from an ongoing late-stage study. The company is seeking approval for obeticholic acid to treat fibrosis or scarring associated with NASH, a serious progressive liver disease caused by excessive fat accumulation in the liver.

Adopting digital transformation is now an industry standard for success – but what precisely does that mean for the clinical development landscape? Gary Shorter, Head of Artificial Intelligence at IQVIA, explores the answers.